midazolam has been researched along with Cerebral Primitive Neuroectodermal Tumor in 1 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Postovsky, S | 1 |
| Moaed, B | 1 |
| Krivoy, E | 1 |
| Ofir, R | 1 |
| Ben Arush, MW | 1 |
1 other study available for midazolam and Cerebral Primitive Neuroectodermal Tumor
| Article | Year |
|---|---|
Practice of palliative sedation in children with brain tumors and sarcomas at the end of life.
Topics: Adolescent; Bone Neoplasms; Brain Neoplasms; Child; Combined Modality Therapy; Consciousness; Glioma | 2007 |